Results 51 to 60 of about 13,683 (246)

AB0865 Do asas, asdas and basdai therapy response evaluation translate the same information? [PDF]

Annals of the Rheumatic Diseases, 2018
Background The ASAS-EULAR recommendations for the continuation of biological Disease-Modifying Anti-rheumatic Drugs (DMARD) suggest the evaluation of patients after at least 12 weeks of treatment by either the Ankylosing Spondylitis (AS) Disease Activity Score – C reactive protein (ASDAS-CRP) or by the Bath AS Disease Activity Index (BASDAI).
Mónica Eusébio, João Lagoas Gomes, Miguel Bernardes, P. Pinto, Helena Santos, José Tavares‐Costa, João Madruga Dias, Sofia Pimenta, Lúcia Domingues, Carolina Lage Crespo, Sara Maia, Fernando Martins, Jaime Branco, Fernando Pimentel‐Santos   +13 more
openalex   +2 more sources

Disease and psychological status in ankylosing spondylitis. [PDF]

, 2006
Objectives. Psychological factors may be important in the assessment and management of ankylosing spondylitis (AS). Our primary objective was to describe associations between disease and psychological status in AS, using AS-specific assessment tools and ...
Goodacre, J. A., Goodacre, L., Grennan, D., Martindale, J., Smith, J., Sutton, Chris J   +5 more
core   +1 more source

HLA-B27 is associated with reduced disease activity in axial spondyloarthritis

Scientific Reports, 2021
HLA-B27 is associated with increased susceptibility and disease activity of ankylosing spondylitis, but the effect of HLA-B27 on the activity of the broader category now called axial spondyloarthritis (AxSpA) is apparently the opposite.
James T. Rosenbaum, Michael H. Weisman, Hedley Hamilton, Cassie Shafer, Elin Aslanyan, Richard A. Howard, Kimberly Ogle, John D. Reveille, Kevin L. Winthrop, Dongseok Choi   +9 more
doaj   +1 more source

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis : 48-week results from the EMBARK study [PDF]

, 2015
Objective: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).
Bonin, Randi, Braun, Jürgen, Bukowski, Jack F, Citera, Gustavo, Dougados, Maxime, Jones, Heather, Kotak, Sameer, Logeart, Isabelle, Maksymowych, Walter P, Marshall, Lisa, Pedersen, Ron, Sieper, Joachim, Van den Bosch, Filip, van der Heijde, Désirée, Vlahos, Bonnie, Wajdula, Joseph   +15 more
core   +1 more source

«FLARES» IN AXIAL SPONDYLOARTHRITIS

Научно-практическая ревматология, 2016
The clear definition of the concept of «flare in axial spondyloarthritis» is of paramount importance for clinical trials and routine practice in particular.
Sh. F. Erdes
doaj   +1 more source

Persistent clinical efficacy and safety of anti-tumour necrosis factor \textgreeka therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response [PDF]

, 2008
Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS).
Alten, R., Baraliakos, X., Braun, J., Burmester, G., Fritz, C., Krause, A., Listing, J., Schewe, Stefan, Schneider, M., Sieper, J., Sörensen, H., Zeidler, H.   +11 more
core   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

Treatment recommendations for psoriatic arthritis [PDF]

, 2008
Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.
Boehncke, Wolf-Henning, Fiorentino, David, FitzGerald, Oliver, Gladman, Dafna D., Gottlieb, Alice B., Helliwell, Philip, Kavanaugh, Arthur, McHugh, Neil J., Mease, Philip J., Nash, Peter, Qureshi, Abrar A., Ritchlin, Christopher T., Soriano, Enrique R., Taylor, William J., Vlam, Kurt de   +14 more
core   +3 more sources

Estimation of disease activity in patients with ankylosing spondylitis in the real practice of a rheumatologist in Russia (Part 2)

Научно-практическая ревматология, 2012
Objective: to compare different methods for estimating ankylosing spondylitis (AS) activity in the real practice of a rheumatologist in the Russian Federation. Subjects and methods.
Evgeny Vladimirovich Volnukhin, E A Galushko, A G Bochkova, A V Smirnov, Sh F Erdes   +4 more
doaj   +1 more source

Evaluation of the Systemic Immune-Inflammation Index and Systemic Inflammatory Response Index in Ankylosing Spondylitis Patients

İstanbul Medical Journal, 2023
Introduction: The aim of this study was to investigate the relationship between the Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) and disease activity in patients with ankylosing spondylitis (AS).
Burak Tayyip Dede, Berat Bulut, Muhammed Oğuz, Fatih Bağcıer, Ebru Aytekin   +4 more
doaj   +1 more source